Table 3 Observational study characteristics
Study | Number of patients | Mean age (years) | Outcome measurea | CYC treatment | Corticosteroid | Length of follow-up (months) |
|---|---|---|---|---|---|---|
Airò and colleagues [15] | 13 | 48 | FVC, 74 | Intravenous, 750 mg/m2 every 3 weeks | Methylprednisolone 125 mg every 3 weeks | 18 |
| Â | Â | Â | DLCO, 41 | Â | Â | Â |
Beretta and colleagues [14] | 33 | 49.7 ± 10.4 | DLCO, 48.8 ± 13.5 | Oral, 2 mg/kg/day | Prednisone 25 mg/day in the first 3 months, 5 mg for 9 months | 12 |
Davas and colleagues, pulse CYC [12] | 8 | NA | FVC, 86.1 | Intravenous, 750 mg/m2 monthly | Prednisone 10 mg/day | 12 |
| Â | Â | Â | DLCO, 60 | Â | Â | Â |
Davas and colleagues, oral CYC [12] | 8 | NA | FVC, 73.2 | Oral, 2 to 2.5 mg/kg/day | Prednisone 10 mg/day | 12 |
| Â | Â | Â | DLCO, 59.9 | Â | Â | Â |
Pakas and colleagues, low-dose prednisone cohort [16] | 12 | 48.6 ± 12.3 | FVC, 54.8 | Intravenous, 900 mg/kg (mean value) | Prednisone low dose, <10 mg/day | 12 |
| Â | Â | Â | DLCO, 38.2 | Â | Â | Â |
Pakas and colleagues, high-dose prednisone cohort [16] | 16 | 48.6 ± 12.3 | FVC, 57.5 | Intravenous, 900 mg/kg (mean value) | Prednisone: high dose, 1 mg/kg/day for 4 weeks | 12 |
| Â | Â | Â | DLCO, 48.3 | Â | Â | Â |
Silver and colleagues [17] | 14 | 46.4 ± 2.4 | FVC, 51.4 ± 2.5 | Oral, 1 to 2 mg/kg/day | Prednisone 7.7 ± 1.2 mg/day (in 10 patients) | 24 |
|  |  |  | DLCO, 54.5 ± 7.4 |  |  |  |
Valentini and colleagues [18] | 13 | 37.4 | DLCO, 58.5 | Intravenous, 500 mg/m2 on day 1, day 8 and day 15, and every 4 weeks | Low dose corticosteroids (dose not specified) | 12 |